297 results on '"Attar, Ricardo"'
Search Results
2. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias
3. SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation
4. Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML.
5. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
6. Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
7. A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma
8. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia
9. Discovery of Alternative Binding Poses through Fragment-Based Identification of DHODH Inhibitors
10. Identification of isoquinolinone DHODH inhibitor isosteres
11. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
12. Crystallographic Structures of the Ligand-Binding Domains of the Androgen Receptor and Its T877A Mutant Complexed with the Natural Agonist Dihydrotestosterone
13. Legends for Supplementary Figures 1-2, Tables 1-6 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
14. Supplementary Figure 2 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
15. Supplementary Figure S1 from BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells
16. Data from BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells
17. Supplementary Tables 1-6 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
18. Supplementary Table S3 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
19. Supplementary Figure 1 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
20. Supplementary Methods from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
21. Data from Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro
22. Supplementary Table 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
23. Supplementary Figure and Table Legends 1-2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
24. Supplementary Tables 1-4 from The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
25. Supplemental Figure S3 from A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
26. Supplementary Table 1 from Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro
27. Data from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
28. Supplemental Table S2 from A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
29. Data from The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
30. Supplementary Figures 1-8 from The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
31. Supplementary Table 2 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
32. Supplementary Figure 1 from Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
33. Setdb1 Suppresses Interferon Responses and Nk Cell-Mediated Immunosurveillance Specifically in Monocytic Aml
34. Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia
35. Macrocyclic Carbon-Linked Pyrazoles As Novel Inhibitors of MCL‑1.
36. Abstract 2133: In pursuit of MCL-1 inhibitors with improved therapeutic window for the treatment of hematological malignancies: Discovery of JNJ-4355
37. Receptor Aggregation Induced by Antilutropin Receptor Antibody and Biological Response in Rat Testis Leydig Cells
38. Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL
39. Abstract 1267: Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas
40. SETDB1 Suppresses Interferon Responses and NK Cell-Mediated Immunosurveillance Specifically in Monocytic AML
41. Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma
42. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar
43. N‑Heterocyclic 3‑Pyridyl Carboxamide Inhibitors of DHODH for the Treatment of Acute Myelogenous Leukemia.
44. Induction and Therapeutic Targeting of Human NPM1c+ Myeloid Leukemia in the Presence of Autologous Immune System in Mice
45. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease
46. Drug Safety Is A Barrier to the Discovery and Development of New Androgen Receptor Antagonists
47. Abstract PO-49: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B-cell lymphomas
48. Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas
49. Abstract 5662: JNJ-67571244: A novel anti-CD33 C2 domain binding bispecific antibody with potent T cell redirection activity
50. FEP+ calculations predict a stereochemical SAR switch for first-in-class indoline NIK inhibitors for multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.